What is BioCryst Pharmaceuticals's SG&A?

BioCryst Pharmaceuticals (BCRX) reported SG&A of $94.55M in Q1 2026.

How has BioCryst Pharmaceuticals's SG&A changed year-over-year?

BioCryst Pharmaceuticals's SG&A increased by 14.7% year-over-year, from $82.47M to $94.55M.

What is the long-term trend for BioCryst Pharmaceuticals's SG&A?

Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's SG&A has grown at a 30.9% compound annual growth rate (CAGR), from $118.82M to $348.65M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

BioCryst Pharmaceuticals BCRX SG&A

SG&A at other companies

Ionis PharmaceuticalsIONS

$150.36M+97.2%

Ultragenyx PharmaceuticalRARE

$88M+1.1%

ANI PharmaceuticalsANIP

$73.66M-3.8%

BridgeBio PharmaBBIO

$163.9M+54.1%

Agios PharmaceuticalsAGIO

$48.3M+16.3%

Arrowhead ResearchARWR

——

Segments

By segment

See full

Reportable Segment$42.95M-9.9%

Other financials

Income statement

See full

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Balance sheet

See full

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Cash flow

See full

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Valuation

See full

Market cap$2.37B+52.3%

Enterprise value$2.6B+46.7%

P/S2.7×-0.4×

Profitability

See full

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Returns & leverage

See full

Return on equity-882.8%—

Debt / equity0.1×—

Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioCryst Pharmaceuticals's SG&A?: BioCryst Pharmaceuticals (BCRX) reported SG&A of $94.55M in Q1 2026.
How has BioCryst Pharmaceuticals's SG&A changed year-over-year?: BioCryst Pharmaceuticals's SG&A increased by 14.7% year-over-year, from $82.47M to $94.55M.
What is the long-term trend for BioCryst Pharmaceuticals's SG&A?: Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's SG&A has grown at a 30.9% compound annual growth rate (CAGR), from $118.82M to $348.65M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.